Should diuretics always be included as initial antihypertensive management in early-stage CKD?

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 5, 2009, Pages 392-396

  Segura, Julian ^a   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Blood pressure control; Chronic kidney disease; Combined antihypertensive therapy; Diuretic; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; EXTRACELLULAR SPACE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; METABOLIC ACIDOSIS; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RISK;

EID: 69549121849     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32832eb7fb     Document Type: Review

References (41)

1. Culleton BF, Larson MG, Wilson PWF, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56:2214-2219.
2. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12. (Pubitemid 36043346)
3. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination survey (NHANES III). J Am Soc Nephrol 2002; 13:1338-1349.
4. Segura J, Campo C, Ruilope LM. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich) 2002; 4:332-336.
5. Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4:672-681. This study describes some strategies to manage traditional and nontraditional cardiovascular risk factor in patients with CKD.
6. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle. Clin J Am Soc Nephrol 2008; 3:505-521. This review focuses on the many new pieces that need to be fit into the complicated puzzle of uremic vascular disease.
7. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15:1307-1315. (Pubitemid 38526012)
8. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351:1296-1305. (Pubitemid 39268908)
9. Astor BC, Hallan SI, Miller ER 3rd, et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167:1226-1234. Recent data confirming that moderately decreased eGFR and albuminuria independently predict cardiovascular and all-cause mortality in the general population.
10. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality in older adults. Arch Intern Med 2008; 168:2212-2218. This study shows the relationship between the decline in eGFR and the increased risk of cardiovascular and all-cause mortality in older adults.
11. Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616-1622. (Pubitemid 38679687)
12. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114:2850-2870.
13. Chobanian A, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
14. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
15. Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994; 23:3-9.
16. Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005; 18 (4 Pt 2):112S-119S.
17. Taal MW. Slowing the progression of adult chronic kidney disease. Therapeutic advances. Drugs 2004; 64:2273-2289.
18. Jafar TH, Stark PC, Schmid CH, et al., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244-252.
19. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16:3027-3037. (Pubitemid 44743500)
20. Wilcox CS. New insights into diuretics use in patients with chronic renal disease. J Am Soc Nephrol 2002; 13:798-805. (Pubitemid 34183949)
21. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 2006; 17:S25-S29.
22. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
23. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535. (Pubitemid 37410190)
24. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1:43-50.
25. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29:1803-1824.
26. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-1007. This study describes some strategies to maximize the antiproteinuric efficacy of renin-angiotensin system blockade.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
28. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207. (Pubitemid 46111014)
29. Bakris GL, Molitch M, Hewkin A, et al., STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29:2592-2597.
30. Bakirs GL, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometabolic Syndr 2008; 3:18-25. This exploratory study suggests that the impairment in glycemic control seen with use of a thiazide diuretic combined with an antiangiotensin drug can be reversed by switching to a regimen that does not include a diuretic.
31. Wu-Wong JR. Endothelial dysfunction and chronic kidney disease: treatment options. Curr Opin Investig Drugs 2008; 9:970-982. This review summarizes most relevant therapies to improve endothelial function in patients with CKD.
32. Miwa Y, Masai H, Shimizu M. Differential effects of calcium-channel blockers on vascular endothelial function in patients with coronary spastic angina. Circ J 2009; 73:713-717. This study describes differences among calcium channel blocker classes on beneficial effects for vascular endothelial function.
33. Besler C, Doerries C, Giannotti G, et al. Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev Cardiovasc Ther 2008; 6:1071-1082. This study reviews evidence suggesting that bone marrow-derived endothelial progenitor cells promote endothelial repair and contribute to ischemia-induced neovascularization.
34. Qian C, Schoemaker RG, van Gilst WH, Rols AJ. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. Clin Sci (Lond) 2009; 116:301-314. This article discusses what is currently known with respect to the role of the renin- angiotensin-aldosterone system in the regulation of cardiovascular progenitor cells.
35. Inaba S, Iwai M, Tomono Y, et al. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens 2009; 22:145-150. This study suggests that the combination of a ARB with calcium channel blockers synergistically inhibits vascular remodeling.
36. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008; 26:494-500. This study demonstrates that thiazide diuretics do not reduce oxidative stress, improve endothelial function, or prevent the expression of proatherogenic molecules. (Pubitemid 351317258)
37. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123. This meta-analysis shows that reduction of BP produces similar protective benefits in younger and older adults.
38. Jamerson K, Weber MA, Bakris GL, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428. This relevant study shows that the benazepril-amlodipine combination was superior to the benazepril- hydrochlorothiazide combination in reducing cardiovascular events in high-risk hypertensive patients.
39. Bakris GL, Hester A, Weber M, et al., ACCOMPLISH Investigators. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr 2008; 3:229-233. This study shows the antihypertensive efficacy of the benazepril-amlodipine combination in high-risk diabetic hypertensive patients.
40. Bakris GL, Kalagitzidis R, Weber M, et al. Renal endpoints in the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial. J Am Soc Nephrol 2008; 19 [abstract].
41. Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis 2005; 46:18-25. (Pubitemid 40848429)